Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1365 Vaccine in Healthy Adults ≥60 Years of Age
NCT07764237Phase 1Recruiting
- Sponsor
- Moderna Inc
- Start
- Aug 2026
- Primary completion
- Jul 2027
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of mRNA-1365 in respiratory syncytial virus infection (RSV) and human metapneumovirus infection (HMPV) (5 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions at Day 7, Number of Participants with Unsolicited Adverse Events at Day 28 and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
mRNA-1365
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT07764237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764237.